• Je něco špatně v tomto záznamu ?

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

DT. Rubin, M. Bradette, L. Gabalec, D. Dobru, J. Márquez, S. Inglis, E. Magee, D. Solomon, G. D'Haens, . ,

. 2016 ; 10 (8) : 925-33. [pub] 20160223

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, klinické zkoušky, fáze IV, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024152

BACKGROUND AND AIMS: This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine. METHODS: In this phase 3b/4, open-label, multicentre, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8g/day once daily for 8 weeks [induction phase]. At Week 8, those who achieved complete or partial remission, based on predefined clinical and endoscopic criteria, were eligible to receive 12 months of multimatrix mesalazine 2.4g/day once daily maintenance therapy. The primary endpoint was the proportion of patients in complete remission at Month 12. RESULTS: A total of 717 patients received induction treatment; 25.9% and 39.3% of patients achieved complete and partial remission, respectively, at Week 8. A total of 461 patients entered the maintenance phase. The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission [47.8% vs 26.0%; p < 0.001]. At Month 12, mucosal healing [endoscopy score ≤ 1] was demonstrated in 76.4% [139/182] and 63.5% [176/277] of those who were in complete and partial remission, respectively, at the end of induction. CONCLUSION: Patients achieving complete remission before dose reduction were more likely to remain in remission at Month 12.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024152
003      
CZ-PrNML
005      
20170906121457.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjw049 $2 doi
035    __
$a (PubMed)26908939
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rubin, David T $u University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA.
245    10
$a Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial / $c DT. Rubin, M. Bradette, L. Gabalec, D. Dobru, J. Márquez, S. Inglis, E. Magee, D. Solomon, G. D'Haens, . ,
520    9_
$a BACKGROUND AND AIMS: This study assessed the efficacy of maintenance treatment with multimatrix mesalazine following achievement of complete or partial remission after induction treatment with high-dose multimatrix mesalazine. METHODS: In this phase 3b/4, open-label, multicentre, prospective, single-arm study, patients with mild-to-moderate ulcerative colitis were treated with multimatrix mesalazine 4.8g/day once daily for 8 weeks [induction phase]. At Week 8, those who achieved complete or partial remission, based on predefined clinical and endoscopic criteria, were eligible to receive 12 months of multimatrix mesalazine 2.4g/day once daily maintenance therapy. The primary endpoint was the proportion of patients in complete remission at Month 12. RESULTS: A total of 717 patients received induction treatment; 25.9% and 39.3% of patients achieved complete and partial remission, respectively, at Week 8. A total of 461 patients entered the maintenance phase. The likelihood of remaining in/achieving complete remission at Month 12 was higher for patients who entered the maintenance phase in complete remission compared with those who began maintenance in partial remission [47.8% vs 26.0%; p < 0.001]. At Month 12, mucosal healing [endoscopy score ≤ 1] was demonstrated in 76.4% [139/182] and 63.5% [176/277] of those who were in complete and partial remission, respectively, at the end of induction. CONCLUSION: Patients achieving complete remission before dose reduction were more likely to remain in remission at Month 12.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antiflogistika nesteroidní $x aplikace a dávkování $x terapeutické užití $7 D000894
650    _2
$a ulcerózní kolitida $x farmakoterapie $7 D003093
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    12
$a indukční chemoterapie $7 D060828
650    12
$a udržovací chemoterapie $7 D060046
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mesalamin $x aplikace a dávkování $x terapeutické užití $7 D019804
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a klinické zkoušky, fáze IV $7 D017429
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bradette, Marc $u CHUQ Research Center, L'Hôtel-Dieu de Québec, Québec, Canada.
700    1_
$a Gabalec, Libor $u Orlickoustecka Nemocnice a.s., Department of Internal Medicine, Ústí nad Orlicí, Czech Republic.
700    1_
$a Dobru, Daniela $u University of Medicine and Pharmacy Târgu Mures, Gastroenterology Department, Târgu Mures, Romania.
700    1_
$a Márquez, Juan $u Department of Colorectal Surgery, Clínica Las Américas, Medellin, Columbia.
700    1_
$a Inglis, Susi $u Shire, Basingstoke, UK.
700    1_
$a Magee, Elizabeth $u Shire, Wayne, PA, USA.
700    1_
$a Solomon, Dory $u Shire, Wayne, PA, USA.
700    1_
$a D'Haens, Geert $u Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands g.dhaens@amc.uva.nl.
700    1_
$a ,
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 10, č. 8 (2016), s. 925-33
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26908939 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906122055 $b ABA008
999    __
$a ok $b bmc $g 1239833 $s 985065
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c 8 $d 925-33 $e 20160223 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20170720
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace